Gossamer Bio is under investigation for allegedly misleading investors about its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The lawsuit claims the company failed to disclose problems with the trial design, particularly issues controlling placebo effects in Latin American sites. This allegedly caused the company's stock price to be artificially inflated. Shareholders who bought stock before June 16, 2025, are encouraged to contact the law firm investigating the case to protect their rights.
GCL Global Holdings' subsidiary 4Divinity has received an additional $9 million investment from ADATA Technology, following previous investments totaling $23 million earlier this year. This latest funding values 4Divinity at $350 million and will be ...
Beazer Homes' Board has agreed to be acquired by Dream Finders Homes in an all-cash deal valued at $33.50 per share, representing a 78% premium over the stock price before the offer. The Donerail Group, a major Beazer shareholder, praised the Board f...
Initta Technology showcased its new AI-driven retail solutions at its annual partner conference in Nanchang, emphasizing its shift from hardware supplier to AI-enabled service provider. The company highlighted its partnership with Intel, using Intel'...
Purpose Investments has launched the Purpose Structured Equity Yield Fund (PSY), the first ETF in Canada to combine actively managed derivatives with a broad portfolio of North American and global securities. This ETF aims to provide tax-efficient mo...
AI Era Corp has established its new headquarters in Menlo Park, Silicon Valley, aiming to enhance its position in AI-driven media and entertainment. This move provides the company better access to top talent, investment opportunities, and closer coll...
